New drug shows promise for ARDS patients in major trial

NCT ID NCT04909697

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This clinical trial tested a drug called sivelestat sodium in 324 adults with acute respiratory distress syndrome (ARDS) and systemic inflammation. The drug aims to block a harmful enzyme that damages lung tissue. Researchers measured whether it improved oxygen levels and reduced the need for a breathing machine.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

sivelestat sodium

What this could lead to

If it works, this could provide a new treatment option for ARDS patients, potentially improving oxygen levels and reducing time on a ventilator.

What could go wrong

This is a completed Phase 4 trial, but results are not yet widely reported. The drug may not show significant benefit over standard care, and side effects are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY DISTRESS SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute respiratory distress syndrome adult acute respiratory distress syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sichuan provincial people's hospital

    Chengdu, Sichuan Privince, China